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Abstract (249 words)  
Background: There are a lack of data regarding the actual durability of bioprosthetic valves in 
younger patients. We sought to assess the long-term durability of pericardial valves in patients at age 
< 65 years undergoing aortic valve replacement (AVR), and to determine the timing of redo 
operations due to structural valve deterioration (SVD). 
Methods: From 1986 to 2001, a total of 574 adult patients underwent AVR with pericardial valves in 
9 hospitals in Japan. Of these, 53 patients were at age < 65 years (group Y). These patients were 
compared with those of age ≥ 65 (group O, n=521).  
Results: The mean follow-up duration was 9.5 years in group Y and 8.1 years in group O. Freedom 
from reoperation due to SVD was 100% at 5 years, 90.8% at 10 years, and 47.2% at 15 years in group 
Y, and 99.3% at 5 years, 97.4% at 10 years, and 94.4% at 15 years in group O (log-rank test, p<0.01). 
In those who required redo AVR in group Y (n=12), the mean time from initial operation to 
reoperation was 12.1 years. The reoperation-free survival curve started to decline after 8 years post-
operation in group Y.  
Conclusions: Redo AVR started to become necessary 8 years after surgery in the patients who 
underwent AVR with pericardial valve at age < 65 years. In addition, approximately a half of those 
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patients had required reoperation due to SVD by 15 years postoperatively. Some of these patients can 
be good candidates for the up-coming technology of the transcatheter intervention. 
 
INTRODUCTION 
The Society of Thoracic Surgeons (STS) recently published clinical practice guidelines for the 
treatment of aortic valves in 2013 [1]. According to the guidelines, a bioprosthesis is recommended 
for aortic valve replacement (AVR) in patients age 65 years or older without risk factors for 
thromboembolism. This consensus itself was first described in the American College of Cardiology 
(ACC)/American Heart Association (AHA) treatment guidelines for valvular heart disease patients 
published in 2006 [2]. These guidelines reflect a significant trend towards tissue valves in elderly 
patients requiring AVR. In fact, the excellent durability of tissue valves, particularly in elderly 
patients, has been well described in many reports published over the last two decades [3-8]. On the 
other hand, a bioprosthesis may be reasonable for AVR in patients at age less than 65 years who 
choose this valve based on lifestyle considerations after detailed discussions. This recommendation 
for patients aged less than 65 years was defined as Class IIa by the 2006 ACC/AHA guidelines, 
whereas this is downgraded, and defined as Class IIb by the 2013 STS guidelines. Also, the most 
recent ACC/AHA guidelines, which was revised in 2014, defines that a bioprosthesis is reasonable 
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in patients more than 70 years of age (class IIa recommendation) [9]. These discrepancies may be 
related to the fact that there are very few data regarding the actual durability of pericardial valves and 
long-term survival in younger patients aged less than 65 or 70 years. We recently published the overall 
results of a Japanese multi-center study to evaluate the long-term durability of pericardial valves in 
aortic position [10]. Thus, the aim of this sub-study analysis was to assess the long-term durability of 
pericardial valves in patients undergoing AVR at age less than 65 years, and to determine the timing 
of redo operation due to structural valve deterioration (SVD). 
 
MATERIALS and METHODS 
We enrolled all patients who underwent AVR with the Carpentier-Edwards PERIMOUNT pericardial 
(CEP) bioprosthesis (Edwards Lifesciences, Irvine, CA, USA) from January 1986 to December 2001 
in the participating 9 hospitals. There were very few types of bioprosthesis available in Japan during 
the study periods. In fact, CEP was the only bioprosthesis used in the aortic position in all the study 
sites. Also, mechanical valves were predominantly used in 1980’s and 1990’s.  The reason we did not 
included the patients who underwent AVR with CEP after 2002 was primarily due to the aim of long-
term follow-up over 10 years in this study focusing on the durability of this bioprosthesis. The details 
of the study were described elsewhere [10]. In short, the total number of patients enrolled was 591. 
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Of these, 574 patients were eligible for this study (17 patients were ineligible due to refusal or lack 
of informed consent). Of note, in addition to the patients who underwent aortic root replacement with 
composite grafts using CEP bioprosthesis, those who underwent concomitant procedures such as 
coronary artery bypass grafting (CABG), mitral or tricuspid valves repair or replacement, and aortic 
aneurysm repair were also included.  Of the 574 patients, 53 patients were age less than 65 years at 
the time of operation (group Y). This group of patients was compared to the other group of patients 
who were 65 years of age or older at the time of operation (group O) in this study. 
 
All the patients’ characteristics and operative data were obtained from medical records at each 
participating hospitals by independent clinical research coordinators according to pre-specified 
criteria. In addition, all of the patients who survived the operation underwent follow-up surveys. Late 
outcomes were determined from medical records when available, from written correspondence with 
patients’ physicians, or direct patient contact via mailed questionnaires or telephone interviews when 
necessary. Clinical data at the latest follow-up were collected by contacting referring physicians. The 
follow-up survey was closed in December 2012.  This study was approved by the Institutional Review 
Board at all the participating hospitals and the Ethics Committee of the Kyoto University Graduate 
School and Faculty of Medicine. All patients or their family members gave informed consent. 
 - 7 - 
 
 
The patients’ baseline characteristics and operative variables in each group are shown in Table 1. In 
terms of the aortic valve pathology, bicuspid aortic valve was relatively more common in group Y. 
Also, active endocarditis was more common in group Y.  On the other hand, calcified tricuspid aortic 
valves were more common in group O. Patients in group O tended to undergo more concomitant 
procedures including CABG and aortic aneurysm repair, whereas mitral valve procedures were more 
commonly performed in group Y, although there were no statistical differences. In terms of the 
reasons of valve selection, the bioprosthesis was chosen most likely due to high age in group O. The 
indications of the bioprosthesis in group Y included desire for child bearing, relatively high age (> 
60 years), limited life expectancy, prior mechanical valve failure, and so on. In particular, there were 
10 patients who were on atrial fibrillation preoperatively in group Y. Of those, the indication of the 
use of bioprosthesis included relatively high age in 6, desire for child bearing in 2, and prior 
mechanical valve failure in 2.   
 
Definitions of Events and Statistical Analysis 
Definitions of SVD and other valve-related events such as thromboembolism or bleeding events were 
based on the STS guidelines for reporting mortality and morbidity after cardiac valve interventions 
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[11].  In short, the term structural valve deterioration refers to changes intrinsic to the valve, such as 
wear, fracture, poppet escape, calcification, leaflet tear, stent creep, and suture line disruption of 
components of a prosthetic valve. Nonstructural dysfunction refers to any abnormality not intrinsic 
to the valve itself that resulted in stenosis or regurgitation of the operated valve or hemolysis. 
Nonstructural dysfunction includes entrapment by pannus, tissue, or suture; paravalvular leakage; 
inappropriate sizing or positioning; residual leakage or obstruction after valve implantation or repair; 
and clinically important intravascular hemolytic anemia. Valve-related death was defined as any 
death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, 
bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; 
or sudden, unexplained death. In-hospital mortality was defined as death occurring within 30 days of 
surgery or at any time during the index hospitalization.  
 
Postoperative overall survival, freedom from valve-related death, valve-related events, and 
reoperation due to SVD were estimated by the Kaplan-Meier method. The associations of potential 
risk factors to survival and events were assessed with log-rank tests. All continuous variables were 
expressed as mean + standard deviation. All p-values are two-sided and a p-value < 0.05 was 
considered statistically significant. All data analysis was carried out by an academic statistician (S.T.) 
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using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS   
As shown in Table 2, there were 2 (3.8%) in-hospital deaths in group Y, and 24 (4.6%) in group O 
(p=0.78). The overall mean and median follow-up duration were 8.2 and 9.2 years, respectively. The 
rate of overall follow-up completeness was 83.1%. Reoperation of the aortic valve prosthesis was 
necessary in 12 patients in group Y, and 12 patients in group O. Of note, only 6 patients out of 12 
who required redo operation in group O actually had SVD as a primary indication. In fact, in group 
O, the other indication for redo AVR included prosthetic valve endocarditis (PVE) in 4 patients, and 
paravalvular leak in one. One patient underwent redo AVR at the time of a mitral valve replacement, 
which was the primary indication of the surgery. In-hospital mortality of redo operations in group Y 
was 8.3% (n=1), whereas it was 16.7% (n=2) in group O. When the patients who required redo AVR 
because of PVE were excluded, the in-hospital mortality was 5.6% overall (8.3% in group Y and 0% 
in group O). The mean duration from the initial operation to the overall redo operation was 12.1+4.3 
years in group Y and 7.7+3.9 years in group O (p=0.013). Of note, in group O, the mean duration 
from the initial operation to the redo operation due to SVD was 9.4+3.3 years. The detailed 
information of each patient who required a redo operation is given in Table 3. 
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Survival curves estimated by the Kaplan-Meier method are shown in Figure 1. Although freedom 
from all-cause death was higher in group Y (log-rank p<0.01), there was no statistical difference in 
freedom from valve-related death between groups (log-rank p=0.45). In addition, there were no 
statistical differences between groups in terms of freedom from thromboembolic events and major 
bleeding events (Figure 2).  As shown in Figure 3 (left), freedom from reoperation due to SVD was 
100% in 5 years, 90.8% in 10 years, and 47.2% in 15 years in group Y, while it was 99.3% in 5 years, 
97.4% in 10 years, and 94.4% in 15 years in group O (log-rank p<0.01). In group Y, the reoperation-
free curve suddenly starts to decline at approximately 8 years post-operation, and more than half of 
the patients in group Y had undergone redo AVR by 15 years post-operation. Also, freedom from 
reoperation due to SVD stratified according to the age at operation is demonstrated in Figure 3 (right). 
 
DISCUSSION 
It is obvious that SVD is inevitable for all tissue valves over time and reoperation becomes necessary 
at some point, however, many elderly patients die before the degree of SVD reaches the point where 
reoperation is indicated. This is one of the reasons why elderly patients benefit most from selecting 
tissue valves over mechanical valves, which require life-long anticoagulation therapy. However, it 
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remains unclear when reoperation becomes necessary in younger patients who undergo AVR with 
tissue valves. In the current study, we demonstrated that in patients aged younger than 65 years who 
underwent AVR with a CEP bioprosthesis, reoperation due to SVD started to become necessary after 
8 years. In these patients requiring reoperation, the mean duration from the initial operation to 
reoperation was approximately 12 years. Also, more than 50% of the patients required reoperation 
due to SVD within 15 years postoperatively.  
 
As an alternative to a pericardial valve, a porcine valve has been the bioprosthesis of choice for years. 
The long-term durability of porcine valves has also been reported to be excellent. David et al. reported 
that freedom from reoperation due to SVD at 20 years in patients who had undergone AVR with 
Hancock II porcine bioprosthetic valves at ages 60-70, and > 70 were 85.2% and 99.8%, respectively 
[12]. There have been very few direct comparisons of the long-term durability between porcine and 
pericardial valves, especially in younger patients [13]. There are a few reports, however, regarding 
the durability of porcine valves in younger patients. Jamieson et al. reported that rates of porcine 
valve failure at 15 years postoperatively are 46% for patients in their fifth decade of life and 42% for 
patients in their sixth decade [14]. Likewise, Fann et al. reported that rates of SVD in porcine valves 
after 15 years were 53% in the fifth decade of life, and 56% in the sixth decade of life [15]. Our results 
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seem to be consistent with those of both aforementioned studies. Therefore, our data support the 
consensus that there are no major differences in terms of the durability between current porcine and 
pericardial valves [16, 17]. Also, there were no survival differences between patients receiving 
porcine valves and patients receiving pericardial valves [18]. In general, the incidence of requiring 
reoperation due to SVD becomes higher when patients are younger [3, 7, 14-17]. In fact, Une et al. 
reported that freedom from reoperation due to SVD in patients receiving porcine bioprosthesis at 20 
years were 41%, 21%, and 14% in the fifth, fourth, and less than third decade of life , respectively 
[18].  It is unknown why the durability is inferior in younger patients. Although it remains anecdotal, 
one can speculate that the pathological process of SVD may be related to the sum of mechanical 
stresses with opening and closing from possible higher heart rates due to more active physical 
activities, and/or metabolic factors involving higher level of calcium metabolisms in younger 
populations that cause leaflet calcification. 
 
There are certain clinical settings where the use of bioprosthesis is mandatory in younger patients 
who have contraindications to warfarin. In fact, a bioprosthesis may be indicated in young women 
who wish to bear a child because of the teratogenicity of warfarin [1, 2]. In the current study, 9 patients 
less than 40 years of age who desired to bear children underwent AVR with a CEP bioprosthesis. Of 
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these, 6 patients required reoperation due to SVD after a mean at 12.4 years (ranged 7.4 to 23.9 years) 
postoperatively with no in-hospital mortality. Based on our data, it seems reasonable to use a CEP 
bioprosthesis in such younger female patients, given the fact that a CEP bioprosthesis gives at least a 
7-year window period during which anticoagulation is unnecessary.  
 
In terms of long-term survival after tissue AVR, the overall survival rate at 15 years was 53.5% in 
the younger group. Jamieson et al. reported that 15-year survival after AVR with porcine 
bioprosthesis at age 51-60 was 46.4% [14], also Suri et al. reported that 15-year survival after tissue 
AVR at age between 40-59 years was 55.0% [20], both of which had similar outcomes to our results. 
It remains unknown why tissue AVR provides poor long-term survival in younger patients. There 
may have been selection bias which did not appear on data. One can speculate that bioprosthetic 
valves had been chosen instead of mechanical prosthesis for some reasons such as possible limited 
life expectancy or poor compliance in those younger patients.  On the other hand, there has been a 
growing body of literature, which may indicate the survival benefit using mechanical prosthesis over 
bioprostheis in younger patients undergoing AVR [20-22].   
 
According to the recent STS guidelines [1], a bioprosthesis is recommended for AVR in patients aged 
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65 years or more without risk factors for thromboembolism. This recommendation is Class I. Also, 
the European Society's guidelines describe that a bioprosthesis is recommended according to the 
desire of the informed patient regardless of the age, which is defined as Class I recommendation [23]. 
Our durability data of pericardial valves stratified according to the age at operation demonstrated that 
patients age > 70 years had almost no chance of reoperation due to SVD (figure 3, right). However, 
some of the patients between 65 and 69 years required reoperation due to SVD after approximately 8 
years up to 12 years, just like the younger patients at age < 65 years. Therefore, patients at age between 
65 and 69 years, in addition to the younger patients at age < 65 years, should also be given the 
information regarding the highly potential need for reoperation due to SVD. In other words, patients 
at age 65 and 69 years may have benefit of higher freedom from reoperation by choosing mechanical 
valves. This finding may support the reasonable indication of the bioprostheses in patients age 70 
years or older, described in the 2014 ACC/AHA guidelines [9].  
 
As shown in Table 3, various types of concomitant procedures may be necessary at the time of redo 
AVR. Especially in patients with a bicuspid aortic valve, replacement of the ascending aorta is often 
indicated concomitantly due to aneurysmal dilatation of the ascending aorta, even when aneurysm 
repair was not indicated at the initial operation. It is well known that patients with a bicuspid aortic 
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valve have a higher tendency to develop aneurysmal dilatation of the aorta in addition to aortic valve 
diseases [1]. According to the STS guidelines, the indication for surgical repair of the ascending aorta 
is a diameter of 5.0 cm and more in patients with a bicuspid aortic valve, whereas it is 5.5 cm 
otherwise [1].  Close follow-up with diagnostic imaging such as CT scan is mandatory in patients 
with aortic valve disease, particularly for those with a bicuspid aortic valve. 
 
Recently, an emerging technology known as transcatheter aortic valve replacement (TAVR) has 
become available in patients with severe symptomatic aortic stenosis (AS) who are considered to be 
inoperable or have higher risk for surgical mortality [24]. Although TAVR is currently approved only 
for patients with native valve severe AS, this technology can be applied to those who have failed 
tissue valves [25]. In fact, a relatively large registry data of TAVR in failed bioprosthetic valves was 
recently published [26]. Although preoperative conditions such as diameter of the aortic annulus, 
vascular access and co-morbidity need to be evaluated in each patient, some of the patients with failed 
bioprosthesis can certainly be excellent candidates for TAVR. It is also expected that newer devices 
with more advanced technology for a wider range of prostheses and a more flexible delivery system 
can resolve many of the current technical limitations in the near future. Yet, the current theoretical 
feasibility of TAVR in our series of patients who had failed CEP bioprosthesis is not well defined. It 
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is true that the small internal diameter of the prosthesis, especially 19mm valve, may preclude a 
candidacy of current valve-in-valve TAVR. Indeed, a small size of the failed bioprosthesis less than 
21mm carried higher short-term and mid-term mortality [26]. Also, those who had prosthetic valve 
infection and paravalvular leakage or concomitant other valvular and/or aortic lesions may not be 
good candidates for valve-in-valve TAVR. Our data certainly suggest that the younger patients who 
had failed tissue valves due to SVD can more likely be candidates for TAVR. It remains unknown, 
however, this valve-in-valve technology would change the indication of bioprosthesis because there 
have been no long-term follow-up data in patients undergoing TAVR. 
 
Limitations 
There were several limitations in this study. First, this was a retrospective, non-randomized study. 
Also, many of the patients died several years prior to the study, and events occurred years before the 
study was performed, making it difficult to obtain accurate information, especially for valve-related 
events. Likewise, the follow-up completeness was somewhat low at 83.1% with 10-year follow-up 
completeness of 82.6%. These factors may have influenced the results significantly. Also, freedom 
from reoperation due to SVD does not mean the real freedom from SVD itself, although it is unlikely 
that reoperation is refused by younger patients if indicated.  




In patients who underwent AVR with CEP bioprosthesis at age < 65 years, redo AVR due to SVD 
started to become necessary after 8 years postoperatively, and approximately a half of the patients 
underwent redo AVR due to SVD by 15 years. Some of these patients can be good candidates for the 
up-coming technology of the transcatheter intervention. 
 
Acknowledgements 
We are indebted to the participating hospitals, investigators, and clinical research coordinators for 
their great contributions to data collection. Participating hospitals: Cardiovascular Center Hokkaido 
Ohno Hospital (Sapporo), Gunma Cardiovascular Center (Maebashi), Funabashi Municipal Medical 
Center (Funabashi), Shizuoka City Shizuoka Hospital (Shizuoka), Nagoya University Hospital 
(Nagoya), Tenri Hospital (Tenri), University Hospital, Kyoto Prefectural University of Medicine  
(Kyoto), Kyoto University Hospital (Kyoto), and Kumamoto Central Hospital (Kumamoto).  
 
Conflict of interest: none declared 
 
Figure legends 
Figure 1. Freedom from all-cause death (left) and valve-related death (right) according to age groups 
 Figure 2. Freedom from thromboembolic events (left) and bleeding events (right) according to age 
groups 
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Figure 3. Freedom from reoperation due to structural valve deterioration according to age groups 
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